Published in AIDS Weekly, July 10th, 2006
In a recent article published in the British Journal of Clinical Pharmacology, scientists in Portugal conducted a study to "investigate the long-term effects of efavirenz on cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL-C) and triglycerides (TG)."
"Thirty-four HIV-infected patients who commenced efavirenz therapy were monitored for 36 months."
"In patients with baseline HDL-C <40 mg/dL-1," wrote S.A. Pereira and colleagues at the New University...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.